Pharmacogenomics: Information sources

Last updated: Wednesday, May 20, 2026

Some Summaries of Product Characteristics may contain helpful information about prescribing medicines according to a patient’s genomic profile (e.g. allopurinol, clopidogrel, citalopram, simvastatin). These may be accessed via the emc or MHRA websites.

The UKCPA Handbook of Pharmacogenomics aims to support the use of pharmacogenetic results to optimise medicines by providing healthcare professionals with evidence-based advice and guidance in a simple and easy to use format. The information provided has been compiled from a range of sources and from the clinical experience of pharmacists and healthcare professionals with expertise in pharmacogenomics. Some of the information contained in the Handbook may not be in accordance with the UK product licence of the drug.

The MHRA have published multiple alerts relating to pharmacogenomics and drug safety. These include: 

Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions [2012]
Tamoxifen for breast cancer [2010] 

Statins: benefits and risks [2014] 

Phenytoin: risk of Stevens-Johnson syndrome associated with HLA-B*1502 allele in patients of Thai or Han Chinese ethnic origin [2010] 

Codeine: restricted use as analgesic in children and adolescents after European safety review [2013] 

Codeine-containing pain relief in children [2012] 

5-fluorouracil (intravenous), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at increased risk of severe and fatal toxicity [2020]

Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations [2021] 

The National Genomics Education Programme’s GeNotes site has an A-Z Knowledge Hub which you can use to refresh your memory or learn about different genomic concepts. The site also has a series of clinical scenarios including some on pharmacogenomics.

ClinPGx replaces what was previously called PharmGKB. In addition, ClinPGx now hosts content from the Clinical Pharmacogenetics Implementation Consortium (CPIC) site. It is a North American specialist pharmacogenomic resource for healthcare professionals and patients. It includes a drug optimisation tool called PharmDOG and a function that enables users to compare pharmacogenomic guidance from different information sources. There is also an option to filter for evidence that specifically relates to children.

Several of NICE’s Clinical Knowledge Summaries may also be helpful to pharmacists and pharmacy technicians working with pharmacogenomic data including that on Familial hypercholesterolaemia, carbamazepine for trigeminal neuralgia and allopurinol for gout. 

Genomics England have an independent Participant Panel who have produced a useful guide on language and terminology when communicating with patients and their families. It is intended for Genomics England staff but may be helpful for healthcare professionals conducting consultations.